Israeli Doctor Presents New Research in Bowel Disease
Dr. Tomer Adar of the Digestive Diseases Institute at Shaare Zedek Medical Center in Jerusalem presented new promising research for treating inflammatory bowel disease at the United European Gastroenterology Week taking place in Berlin, Germany. Fellow researcher Dr. Eran Goldin, chairman of the Digestive Diseases Institute stated, "eotaxin-1 is a biomarker of IBD and a potential target for therapeutic intervention. This new selective approach is promising for patients with moderate to severe ulcerative colitis. We look forward to the Phase II clinical data with bertilimumab."
Other archived news briefs:Oct 16 2013, 07:15 PM, 10/16/2013